Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
non-small cell lung cancer
Biotech
Ultimovacs lays off 40% in wake of cancer vaccine's phase 2 fail
Ultimovacs previously already hinted at a dash to preserve cash following the failure of its cancer vaccine in a phase 2 trial.
James Waldron
Apr 17, 2024 8:22am
Eli Lilly axes next-generation, resistance-busting RET inhibitor
Feb 6, 2024 7:41am
Roche previews Alzheimer's drug that 'drops plaque like a stone'
Feb 1, 2024 11:30am
Gilead stops phase 3 TIGIT trial, doubles down on other studies
Jan 30, 2024 8:09am
Arrivent unveils $135M IPO pricing to get furmonertinib to FDA
Jan 22, 2024 10:28am
Disco gets down with €20M to find targets for cancer therapy
Jan 16, 2024 3:30am